In the clinical perspectives of DPP4 inhibitors in the prevention and treatment of HCC, a nationwide study in Taiwan demonstrated that DPP4 inhibitors decreased the risk of HCC in patients with chronic hepatitis C and type 2 diabetes mellitus [51]. This evidence concerns the gene DPP4 and chronic hepatitis C virus infection.